News & Media
Read the latest news from Cell to Cure.
Filters
Nov 03, 2023
Cell2Cure has treated the first patients with autism spectrum disorders and signs of leaky gut syndrome in a Phase I trial
Feb 09, 2023
Cell2Cure has treated the first patient with diabetic foot ulcer in the STEMFOOT (Phase I study)
Nov 30, 2022
The Danish Medicines Agency has approved the phase I clinical trial with allogeneic adipose tissue-derived mesenchymal stromal/stem cell (ASC) treatment of children with autism and leaky gut syndrome
Nov 04, 2022
Ethical approval for the allogeneic adipose tissue-derived mesenchymal stromal/stem cell (ASC) phase I clinical trial in children with autism and leaky gut syndrome
Sep 21, 2022
The Danish Medicines Agency has approved a Phase I trial treating diabetic foot ulcer with allogeneic adipose tissue-derived mesenchymal stromal/stem cells (ASCs)
Jun 17, 2022
Patient enrollment finalized in the Phase II trial testing allogeneic adipose tissue-derived mesenchymal stromal/stem cells (ASCs) in Sjögren’s syndrome
Apr 29, 2022
Publication of phase I results of allogeneic adipose tissue-derived mesenchymal stromal/stem cell (ASC) treatment of patients with radiation-induced Xerostomia
Feb 10, 2021
Allogeneic adipose tissue-derived mesenchymal stromal/stem cell (ASCs) in Phase II testing in Salivary gland re-generation
Feb 01, 2021
Completion of allogeneic adipose tissue-derived mesenchymal stromal/stem cell (ASCs) in a Heart failure trial
Jan 10, 2021
Allogeneic adipose tissue-derived mesenchymal stromal/stem cell (ASCs) in a lung transplantation trial
Nov 01, 2020
